BibTex format
@article{Fabbri:2023:10.1136/thoraxjnl-2021-218275,
author = {Fabbri, L and Moss, S and Khan, FA and Chi, W and Xia, J and Robinson, K and Smyth, AR and Jenkins, G and Stewart, I},
doi = {10.1136/thoraxjnl-2021-218275},
journal = {Thorax},
pages = {191--201},
title = {Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis},
url = {http://dx.doi.org/10.1136/thoraxjnl-2021-218275},
volume = {78},
year = {2023}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Introduction Persisting respiratory symptoms in COVID-19 survivors may be related to development of pulmonary fibrosis. We assessed the proportion of chest CT scans and pulmonary function tests consistent with parenchymal lung disease in the follow-up of people hospitalised with COVID-19 and viral pneumonitis.Methods Systematic review and random effects meta-analysis of proportions using studies of adults hospitalised with SARS-CoV-2, SARS-CoV, MERS-CoV or influenza pneumonia and followed up within 12 months. Searches performed in MEDLINE and Embase. Primary outcomes were proportion of radiological sequelae on CT scans; restrictive impairment; impaired gas transfer. Heterogeneity was explored in meta-regression.Results Ninety-five studies (98.9% observational) were included in qualitative synthesis, 70 were suitable for meta-analysis including 60 SARS-CoV-2 studies with a median follow-up of 3 months. In SARS-CoV-2, the overall estimated proportion of inflammatory sequelae was 50% during follow-up (0.50; 95% CI 0.41 to 0.58; I2=95%), fibrotic sequelae were estimated in 29% (0.29; 95% CI 0.22 to 0.37; I2=94.1%). Follow-up time was significantly associated with estimates of inflammatory sequelae (−0.036; 95% CI −0.068 to –0.004; p=0.029), associations with fibrotic sequelae did not reach significance (−0.021; 95% CI −0.051 to 0.009; p=0.176). Impaired gas transfer was estimated at 38% of lung function tests (0.38 95% CI 0.32 to 0.44; I2=92.1%), which was greater than restrictive impairment (0.17; 95% CI 0.13 to 0.23; I2=92.5%), neither were associated with follow-up time (p=0.207; p=0.864).Discussion Sequelae consistent with parenchymal lung disease were observed following COVID-19 and other viral pneumonitis. Estimates should be interpreted with caution due to high heterogeneity, differences in study casemix and initial severity.
AU - Fabbri,L
AU - Moss,S
AU - Khan,FA
AU - Chi,W
AU - Xia,J
AU - Robinson,K
AU - Smyth,AR
AU - Jenkins,G
AU - Stewart,I
DO - 10.1136/thoraxjnl-2021-218275
EP - 201
PY - 2023///
SN - 0040-6376
SP - 191
TI - Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis
T2 - Thorax
UR - http://dx.doi.org/10.1136/thoraxjnl-2021-218275
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000774770000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://thorax.bmj.com/content/early/2022/03/24/thoraxjnl-2021-218275
UR - http://hdl.handle.net/10044/1/98250
VL - 78
ER -